A Single-Dose, Randomized, Open-Label, Two-Period Crossover, Bioequivalence Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants
Latest Information Update: 28 Jun 2023
At a glance
- Drugs Olezarsen (Primary)
- Indications Cardiovascular disorders; Hyperlipoproteinaemia type I; Hypertriglyceridaemia
- Focus Pharmacokinetics
- Sponsors Ionis Pharmaceuticals
Most Recent Events
- 21 Jun 2023 Status changed from active, no longer recruiting to completed.
- 24 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 29 Nov 2022 Status changed from not yet recruiting to recruiting.